Surgery Publications

Title

Use of OKT3 Monoclonal Antibody as Induction Therapy for Control of Rejection in Liver Transplantation

Document Type

Article

Publication Date

1995

Journal

Digestive Diseases and Sciences

Volume

40

Issue

1

First Page

52

Last Page

57

URL with Digital Object Identifier

http://dx.doi.org/10.1007/BF02063941

Abstract

This report details a single center's experience with OKT3 induction immunosuppression for liver transplantation. One hundred ninety-nine consecutive, unselected adult liver recipients received OKT3 therapy for 9-10 days combined with low-dose steroids and azathioprine. Cyclosporine was begun to overlap with the last few days of OKT3 therapy. The average dose of OKT3 was 45 mg. Fifty-two patients (26.1%) experienced 57 episodes of acute rejection. The median time of onset of rejection was 18 days after grafting. Seventy-eight percent of the rejection episodes were steroid-sensitive. Recurrent rejection was uncommon and the need for OKT3 retreatment was infrequent. One year actuarial graft and patient survival was 79.7% and 82.3% respectively. Based on this evidence, it appears that OKT3 prophylaxis provides good control of acute rejection with a very low incidence of recurrent rejection.

Notes

Dr. Vivian McAlister is currently a faculty member at The University of Western Ontario.